# Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

> **NCT06068621** · PHASE2 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 200 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- **DRUG:** "3+7"

## Key facts

- **NCT ID:** NCT06068621
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2024-05-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- 940 Hospital of the People's Liberation Army Joint Logistic Support Force
- The General Hospital of Western Theater Command
- The General Hospital of Northern Theater Command
- 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Air Force Military Medical University, China
- Yantai Yuhuangding Hospital
- People's Liberation Army (PLA) Strategic Support Force Characteristic Medical Center
- First Hospital of China Medical University

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068621, "Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06068621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*